There was a difference of 2 % or less in class-specific adverse events associated with anti-VEGF therapy ( hypertension , proteinuria , wound-healing complications , thrombotic events , gastrointestinal perforations ) , except bleeding , which was more common in the placebo group than in the trebananib group ( 75 [ 17 % ] vs 46 [ 10 % ] ) .